Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency

OncoImmunology

Volumn 3, Issue 10, 2014, Pages e959321-1-e959321-12

  Zhang, Yi ^a   Tian, Shenghe ^a   Liu, Zuqiang ^a   Zhang, Jiying ^a   Zhang, Meili ^b   Bosenberg, Marcus W ^c   Kedl, Ross M ^d   Waldmann, Thomas A ^b   Storkus, Walter J ^a,e   Falo, Louis D ^a,e   You, Zhaoyang ^a,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer vaccines; DC; IL 15

Indexed keywords

B RAF KINASE; CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; DOPACHROME TAUTOMERASE; INTERLEUKIN 15; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD8 T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN CELL; IMMUNIZATION; INOCULATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE;

EID: 84931391331     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.959321     Document Type: Article

References (58)

1. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
2. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
3. P.A.Savage. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013; 34:33-40; PMID:22999714; http://dx.doi.org/10.1016/j.it.2012.08.005
4. + T cells: when, where, and how. Annu Rev Immunol 2006; 24:519-40; PMID:16551258; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115825
5. M.A.Cheever. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008.; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
6. T.A.Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901
7. + T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006; 12:335-41; PMID:16474399; http://dx.doi.org/10.1038/nm1359
8. + T cells to differentiate into CTL. Eur J Immunol 2007; 37:1678-90; PMID:17492620; http://dx.doi.org/10.1002/eji.200636329
9. + T cells activated by IL-15 through receptor β/common γ signaling in trans. J Immunol 2008; 181:8237-47; PMID:19050240; http://dx.doi.org/10.4049/jimmunol.181.12.8237
10. S.Tian, Z.Liu, C.Donahue, H.S.Noh, L.D.FaloJr, Z.You. Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther 2009; 16:1260-70; PMID:19727134; http://dx.doi.org/10.1038/gt.2009.110
11. J.C.Steel, C.A.Ramlogan, P.Yu, Y.Sakai, G.Forni, T.A.Waldmann, J.C.Morris. Interleukin-15 signaling augments dendritic cell vaccination against HER2/Neu by inducing Her2/Neu antibodies. Cancer Res 2010; 70:1072-81; PMID:20086176; http://dx.doi.org/10.1158/0008-5472.CAN-09-1301
12. + T cell responses. J. Leukoc. Biol 2011; 89:205-14; PMID:21474552; http://dx.doi.org/10.1189/jlb.1010579
13. P.Yu, J.C.Steel, M.Zhang, J.C.Morris, T.A.Waldmann. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 24:6019-28; PMID:20924130; http://dx.doi.org/10.1158/1078-0432.CCR-10-1966
14. + T cells. J Exp Med 2001; 193:219-31; PMID:11208862; http://dx.doi.org/10.1084/jem.193.2.219
15. S.Roychowdhury, B.W.Blaser, A.G.Freud, K.Katz, D.Bhatt, A.K.Ferketich, V.Bergdall, D.Kusewitt, R.A.Baiocchi, M.A.Caligiuri. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-vs.-host disease. Blood 2005; 106:2433-35; PMID:15976176; http://dx.doi.org/10.1182/blood-2005-04-1597
16. + T-cell leukemia in IL-15 transgenic mice requires the cis-expression of IL-15Rα. Blood 2011; 117:4032-40; PMID:21304101; http://dx.doi.org/10.1182/blood-2010-09-307504
17. A.Mishra, S.Liu, G.H.Sams, D.P.Curphey, R.Santhanam, L.J.Rush, D.Schaefer, L.G.Falkenberg, L.Sullivan, L.Jaroncyk, Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 2012; 22:645-55; PMID:23153537; http://dx.doi.org/10.1016/j.ccr.2012.09.009
18. T.A.Waldmann, E.Lugli, M.Roederer, L.P.Perera, J.V.Smedley, R.P.Macallister, C.K.Goldman, B.R.Bryant, J.M.Decker, T.A.Fleisher, Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011; 117:4787-95; PMID:21385847; http://dx.doi.org/10.1182/blood-2010-10-311456
19. M.P.Rubinstein, M.Kovar, J.F.Purton, J.H.Cho, O.Boyman, C.D.Surh, J.Sprent. Converting IL-15 to a superagonist by binding to soluble IL-15R{α}. Proc Natl Acad Sci USA 2006; 103:9166-71; PMID:16757567; http://dx.doi.org/10.1073/pnas.0600240103
20. + T cells. Cancer Res 2008; 68:2972-83; PMID:18413767; http://dx.doi.org/10.1158/0008-5472.CAN-08-0045
21. A.Bessard, V.Solé, G.Bouchaud, A.Quéméner, Y.Jacques. High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275
22. V.Kermer, V.Baum, N.Hornig, R.E.Kontermann, D.Müller. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; 11:1279-88; PMID:22491823; http://dx.doi.org/10.1158/1535-7163.MCT-12-0019
23. W.Xu, M.Jones, B.Liu, X.Zhu, C.B.Johnson, A.C.Edwards, L.Kong, E.K.Jeng, K.Han, W.D.Marcus, Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013; 73:3075-86; PMID:23644531; http://dx.doi.org/10.1158/0008-5472.CAN-12-2357
24. E.Mortier, T.Woo, R.Advincula, S.Gozalo, A.Ma. IL-15Ralphachaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205:1213-25; PMID:18458113; http://dx.doi.org/10.1084/jem.20071913
25. + T-cell homeostasis via IL-15 transpresentation. Blood 2008; 112:4546-54; PMID:18812469; http://dx.doi.org/10.1182/blood-2008-05-156307
26. + T cell immune responses. Eur J Immunol 2003; 33:3493-503; PMID:14635060; http://dx.doi.org/10.1002/eji.200324545
27. S.P.Dubois, T.A.Waldmann, J.R.Müller. Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci USA 2005; 102:8662-67; PMID:15932944; http://dx.doi.org/10.1073/pnas.0503360102
28. T.Ohteki, H.Tada, K.Ishida, T.Sato, C.Maki, T.Yamada, J.Hamuro, S.Koyasu. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo. J Exp Med 2006; 203:2329-38; PMID:16966429; http://dx.doi.org/10.1084/jem.20061297
29. K.U.Saikh,, T.L.Kissner, S.Nystrom, G.Ruthel, R.G.Ulrich. Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers. Clin Vaccine Immunol 2008; 15:131-37; PMID:18045883; http://dx.doi.org/10.1128/CVI.00320-07
30. + T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 2008; 105:5201-06; PMID:18362335; http://dx.doi.org/10.1073/pnas.0801003105
31. V600E cooperates with Pten loss to induce metastatic melanoma. Nat Genetics 2009; 41:544-52; PMID:19282848; http://dx.doi.org/10.1038/ng.356
32. + T cells produces antigen-inexperienced T cells in the periphery with memory phenotype and function. J Immunol 2013; 190:1936-47; PMID:23355737; http://dx.doi.org/10.4049/jimmunol.1203149
33. + memory T cells. Proc Natl Acad Sci USA 2007; 104:588-93; PMID:17202253
34. R.Prins,, S.K.Odesa, L.M.Liau. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63:8487-91; PMID:14679014
35. J.H.Kim, N.Majumder, H.Lin, J.Chen, L.D.FaloJr, Z.You. Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 2005; 11:941-49; PMID:15922965; http://dx.doi.org/10.1016/j.ymthe.2005.01.003
36. J.H.Kim, N.Majumder, H.Lin, S.Watkins, L.D.FaloJr, Z.You. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Human Gene Ther 2005; 16:1255-66; PMID:16259559; http://dx.doi.org/10.1089/hum.2005.16.1255
37. L.Wang, L.Rollins, Q.Gu, S.Y.Chen, X.F.Huang. A Mage3/heat shock protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine 2010; 28:561-70; PMID:19835823; http://dx.doi.org/10.1016/j.vaccine.2009.09.119
38. + T cell help. J Immunol 2005.; 175:112-23; PMID:15972637; http://dx.doi.org/10.4049/jimmunol.175.1.112
39. M.W.Lipscomb, L.Chen, J.L.Taylor, C.Goldbach, S.C.Watkins, P.Kalinski, L.H.Butterfield, A.K.Wesa, W.J.Storkus. Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. J Immunol 2009; 183:7250-58; PMID:19915058; http://dx.doi.org/10.4049/jimmunol.0901477
40. A.T.Larregina, S.C.Watkins, G.Erdos,L.A.Spencer, W.J.Storkus, D.Beer Stolz, L.D.FaloJr. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 2001; 8:608-17; PMID:11320407; http://dx.doi.org/10.1038/sj.gt.3301404
41. Z.Liu, J.H.Kim, L.D.FaloJr, Z.You. Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 2009; 182:6160-67; PMID:19414769; http://dx.doi.org/10.4049/jimmunol.0802664
42. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13:4345-54; PMID:17671115; http://dx.doi.org/10.1158/1078-0432.CCR-07-0472
43. S.Tian, Z.Liu, C.Donahue, L.D.FaloJr, Z.You. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther 2012; 20:432-42; PMID:21934655; http://dx.doi.org/10.1038/mt.2011.183
44. + dendritic cells in cytotoxic T cell immunity. Science 2008; 322:1097-100; PMID:19008445; http://dx.doi.org/10.1126/science.1164206
45. + dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; http://dx.doi.org/10.1084/jem.20101159
46. M.S.Diamond, M.Kinder, H.Matsushita, M.Mashayekhi, G.P.Dunn, J.M.Archambault, H.Lee, C.D.Arthur, J.M.White, U.Kalinke, Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158
47. S.Kuwajima, T.Sato, K.Ishida, H.Tada, H.Tezuka, T.Ohteki. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 2006; 7:740-46; PMID:16715101; http://dx.doi.org/10.1038/ni1348
48. M.Zhang, Z.Yao, S.Dubois, W.Ju, J.R.Müller, T.A.Waldmann. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA 2009; 106:7513-18; PMID:19383782; http://dx.doi.org/10.1073/pnas.0902637106
49. P.Yu, J.C.Steel, M.Zhang, J.C.Morris, R.Waitz, M.Fasso, J.P.Allison, T.A.Waldmann. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA 2012; 109:6187-92; PMID:22474386; http://dx.doi.org/10.1073/pnas.1203479109
50. R.B.Liu, B.Engels, K.Schreiber, C.Ciszewski, A.Schietinger, H.Schreiber, B.Jabri. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci USA 2013; 110:8158-63; PMID:23637340; http://dx.doi.org/10.1073/pnas.1301022110
51. J.C.Morris, C.A.Ramlogan-Steel, P.Yu, B.A.Black, P.Mannan, J.P.Allison, T.A.Waldmann, J.C.Steel. Vaccination with tumor cells expressing IL-15 and IL-15Ra inhibits murine breast and prostate cancer. Gene Ther 2014; 21:393-401; PMID:24572789; http://dx.doi.org/10.1038/gt.2014.10
52. K.M.J.Conlon. Phase I study of intravenous recombinant human interleukin-15 (rhIL-15) in adults with metastatic malignant melanoma and renal cell carcinoma. J Immunother 2012; 35:102-03.
53. + T cell subsets. Immunity 2009; 31:811-22; PMID:19913445; http://dx.doi.org/10.1016/j.immuni.2009.09.017
54. R.W.DePaolo, V.Abadie, F.Tang,H.Fehlner-Peach, J.A.Hall, W.Wang, E.V.Marietta, D.D.Kasarda, T.A.Waldmann, J.A.Murray, Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011; 471:220-24; PMID:21307853; http://dx.doi.org/10.1038/nature09849
55. A.M.Ring, J.X.Lin, D.Feng, S.Mitra, M.Rickert, G.R.Bowman, V.S.Pande, P.Li, I.Moraga, R.Spolski, Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012; 13:1187-95; PMID:23104097; http://dx.doi.org/10.1038/ni.2449
56. +T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-36; PMID:12532024; http://dx.doi.org/10.1126/science.1078231
57. C.L.Mackall. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000; 18:10-18; PMID:10661568; http://dx.doi.org/10.1634/stemcells.18-1-10
58. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761-70; PMID:15365095; http://dx.doi.org/10.1084/jem.20041196